Robot-assisted radical hysterectomy reduced mostly low-grade intraoperative complications vs open surgery in early-stage cervical cancer.
|Articles|April 20, 2011
Are you treating breast cancer patients with Avastin? If so, how?
Many doctors are currently struggling with how to use Avastin to treat their breast cancer patients after the recent FDA ruling. If you are currently using Avastin to treat breast cancer patients, please share your thoughts on treatment options and combinations here.
Advertisement
Many doctors are currently struggling with how to use Avastin to treat their breast cancer patients after the recent FDA ruling. If you are currently using Avastin to treat breast cancer patients, please share your thoughts on treatment options and combinations here.
Are you still treating breast cancer patients with Avastin? And if so, how?
Advertisement
Related to this article
Ralph V. Boccia, MD, FACP, explained why CAR T-cell therapy followed by bispecific antibodies may be the preferred sequence at first relapse in multiple myeloma.
The NCCN published its first guidelines for pediatric bone sarcoma, centering on Ewing sarcoma and other undifferentiated round cell sarcomas in youth for pediatric patients.
Investigators of the phase 3 ACTION-1 trial will continue to follow up with patients to assess overall survival outcomes with RYZ101.
Ralph V. Boccia, MD, FACP, details remote monitoring, ICE scoring, CRS prophylaxis, and IVIG strategies for patients receiving bispecifics.
An expert panel discusses the case for de-escalating antibiotic therapy for pediatric patients who undergo hematopoietic cell transplantation.
Ralph V. Boccia, MD, FACP, discusses step-up dosing workflows, REMS, staff training, caregivers, and hospital partnerships for bispecifics.
Ralph V. Boccia, MD, FACP, discusses CAR T and bispecific sequencing, fixed-duration therapy, MRD, and bispecifics in AL amyloidosis.
Advertisement
Advertisement
Trending on CancerNetwork
1
Larger Prostates Showed Post-Radiotherapy Urinary Symptom Normalization
2
Sequencing Bispecifics and CAR T-Cell Therapy in Myeloma and AL Amyloidosis
3
Weighing the Promise and Trade-offs of CAR NK Cell Therapy for Cancer
4
Building a Low-Dose Radiation Therapy Program for Benign Disease
5